Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen ...

Cathie Wood and Ark Invest seized the opportunity on Tuesday to buy the dip on Tempus AI (NASDAQ:TEM) as the stock took a 15% ...

DeepSeek is a stark reminder about the importance of strategic durability, and not just growth or growth potential, to a ...

Tempus AI (NASDAQ:TEM – Get Free Report) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating ...

Key Takeaways Tempus AI's fourth-quarter results missed estimates as its costs increased.The medical technology firm's ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

According to GlobalData forecasts, the pharmaceutical industry is expected to spend over $407m on AI platforms by 2028.

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) saw unusually-strong trading volume on Tuesday after Needham & Company LLC raised their price target on the stock from $56.00 to $70.00. Needham & ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

Despite optimistic news from the CEO yesterday afternoon, the company's shares fell overnight and a major investment house ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Popular investor Cathie Wood and her Ark Invest funds took advantage of a buying opportunity on Tuesday by purchasing over 400,000 shares of ...